There are currently several Food and Drug Administration (FDA) approved TNF-α, IL-1 and IL-6 inhibitors for clinical indications such as rheumatic diseases, Crohn's disease and cryopyrin-associated periodic syndromes (CAPS) [184]. The gene discussed is IL6; the disease is cryopyrin-associated periodic syndrome.